Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on novel serotonergic agonists (NSAs) for mental health conditions, has appointed Michael Halstead as chief executive officer, effective immediately. The announcement comes as the company advances its lead candidate, HLP003, through Phase 3 development and prepares for potential commercialization. Halstead brings 25 years of biopharmaceutical leadership, including his recent role as president of Intra-Cellular Therapies, where he oversaw the development and commercialization of CAPLYTA, supported pipeline expansion, and helped lead the company's $14.6 billion acquisition by Johnson & Johnson in 2025.
Halstead's appointment coincides with significant clinical milestones for Helus Pharma. Enrollment is complete in the Phase 3 APPROACH trial for HLP003, with topline data expected in Q4 2026. Enrollment is also continuing in the EMBRACE pivotal study. Additionally, the company is advancing HLP004, another proprietary NSA, for generalized anxiety disorder (GAD). HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the adjunctive treatment of major depressive disorder (MDD).
This leadership change is strategically important for Helus Pharma as it transitions from a clinical-stage company to one potentially approaching commercialization. Halstead's experience in launching CAPLYTA, a treatment for bipolar depression and major depressive disorder, is directly relevant to HLP003's target indication. His track record in building commercial infrastructure and navigating regulatory pathways will be critical as the company prepares for potential market entry. The appointment also signals confidence in the company's pipeline and its ability to execute on its late-stage development plans.
The implications for the mental health treatment landscape are notable. HLP003 represents a new class of therapeutics – synthetic molecules designed to activate serotonin pathways and promote neuroplasticity. If approved, it could offer a novel adjunctive treatment for MDD, a condition affecting millions worldwide. The company's focus on durable improvements in mental health aligns with the growing demand for more effective and longer-lasting therapies. With the global mental health crisis escalating, innovative treatments like HLP003 could address significant unmet needs.
For investors and industry observers, Halstead's appointment is a positive signal. His leadership at Intra-Cellular Therapies culminated in a major acquisition, demonstrating his ability to drive value creation. Helus Pharma's progress in Phase 3 trials, combined with experienced leadership, positions the company to potentially deliver significant returns. However, the company still faces regulatory hurdles and the inherent risks of clinical development. The upcoming topline data from the APPROACH trial will be a key catalyst.
Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and operates in Canada, the United States, the United Kingdom, and Ireland. The company is committed to addressing the large unmet need for people suffering from depression, anxiety, and other mental health conditions. Its proprietary NSAs aim to provide durable improvements in mental health. For more information, visit https://nnw.fm/wCjAp.
